INTELLIGENT BIO SOLUTIONS INC. Finance Lease, Right-of-Use Asset, Amortization
INTELLIGENT BIO SOLUTIONS INC. (INBS) reported Finance Lease, Right-of-Use Asset, Amortization of $288.93 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-12
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $243.46K, a 301.82% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $45.47K, a 26.05% decline year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-06-30 was $62.26K, a 4.05% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-03-31 was $59.29K, a 1.28% decline year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $243.63K, a 2.05% increase from fiscal 2024.
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $238.73K, a 56.80% increase from fiscal 2023.
- INTELLIGENT BIO SOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $152.25K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $243.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $288.93K 10-Q · filed 2026-02-12 | $351.19K derived: sum of 3 quarters · filed 2026-02-12 | $410.48K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-09-30 | $45.47K 10-Q · filed 2025-11-12 | $107.73K derived: sum of 2 quarters · filed 2025-11-12 | $167.03K derived: sum of 3 quarters · filed 2025-11-12 | $227.61K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $62.26K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-15 | $121.56K derived: sum of 2 quarters · filed 2025-08-15 | $182.14K derived: sum of 3 quarters · filed 2025-08-15 | $243.63K 10-K · filed 2025-08-15 |
| 2025-03-31 | $59.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $119.88K derived: sum of 2 quarters · filed 2025-05-13 | $181.37K 10-Q · filed 2025-05-13 | $241.21K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | $60.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-13 | $122.08K 10-Q · filed 2025-02-13 | $181.92K derived: sum of 3 quarters · filed 2025-11-12 | $241.98K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-09-30 | $61.49K 10-Q · filed 2025-11-12 | $121.33K derived: sum of 2 quarters · filed 2025-11-12 | $181.39K derived: sum of 3 quarters · filed 2025-11-12 | $240.26K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $59.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-15 | $119.90K derived: sum of 2 quarters · filed 2025-08-15 | $178.77K derived: sum of 3 quarters · filed 2025-08-15 | $238.73K 10-K · filed 2025-08-15 |
| 2024-03-31 | $60.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $118.93K derived: sum of 2 quarters · filed 2025-05-13 | $178.89K 10-Q · filed 2025-05-13 | $236.97K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $58.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-13 | $118.83K 10-Q · filed 2025-02-13 | $176.91K derived: sum of 3 quarters · filed 2025-02-13 | $222.46K derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $59.96K 10-Q · filed 2024-11-07 | $118.04K derived: sum of 2 quarters · filed 2024-11-07 | $163.59K derived: sum of 3 quarters · filed 2024-11-07 | $212.21K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $58.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $103.63K derived: sum of 2 quarters · filed 2024-09-18 | $152.25K derived: sum of 3 quarters · filed 2024-09-18 | $152.25K 10-K · filed 2024-09-18 |
| 2023-03-31 | $45.55K 10-Q · filed 2023-05-11 | $94.17K derived: sum of 2 quarters · filed 2023-05-11 | $94.17K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $48.62K 10-Q · filed 2023-02-14 | $48.62K 10-Q · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |